Tylenol, Theraflu, NyQuil, and DayQuil
Allegations: Falsely marketing that phenylephrine products treat nasal congestion
Wilson et al. v. Johnson & Johnson Consumer, Inc. et al.
23-cv-21276, D.N.J.
(Oct. 2023)
Children’s Dimetapp, DayQuil, Mucinex, Mucinex Children’s, and Sudafed
Falsely marketing that phenylephrine products treat nasal congestion when phenylephrine is not an effective decongestant when taken orally
Pending
Allegations: Falsely marketing that phenylephrine products treat nasal congestion
Allegations: Falsely marketing that medicines treat nasal congestion
Allegations: Falsely marketing that medicines are decongestants
Allegations: Falsely marketing the products treat nasal congestion
Allegations: Falsely marketing that phenylephrine products treat congestion and other cold and flu symptoms
Allegations: Falsely marketing that medicines treat nasal congestion
Allegations: Falsely marketing that medicines treat nasal congestion
Allegations: Misleadingly marketing drink mixes using the phrase “Natural fruit flavor” and images of raspberries when they contain artificial flavoring ingredients
Allegations: Misleadingly marketing products as if they treat symptoms of coughs and colds
Allegations: False natural claims
Allegations: False natural claims
A closer look at what we’ll be monitoring in the new year.
Some class-action settlements that left consumers behind.
What consumers should know about software tethering.
The bottom line? Toothpaste tubes aren’t generally getting recycled.
Lawsuit alleges environmental claims don’t stick.